CN Patent
CN104906064B — 一种普瑞巴林胃漂浮缓释片剂及其制备方法
Assigned to China Pharmaceutical University · Expires 2017-12-22 · 8y expired
What this patent protects
本发明涉及一种日服一次的普瑞巴林胃漂浮缓释制剂及其制备方法。该普瑞巴林胃漂浮缓释制剂包括如下重量百分比的成分:普瑞巴林5~40%,10~40%骨架材料,1~20%膨胀剂,10~40%助漂剂,5~40%稀释剂。该新颖口服制剂可实现将普瑞巴林延迟释放的特性,并能够延长普瑞巴林在胃和小肠上端的滞留时间,提高生物利用度,获得平稳的血药浓度,减少服用次数。
USPTO Abstract
本发明涉及一种日服一次的普瑞巴林胃漂浮缓释制剂及其制备方法。该普瑞巴林胃漂浮缓释制剂包括如下重量百分比的成分:普瑞巴林5~40%,10~40%骨架材料,1~20%膨胀剂,10~40%助漂剂,5~40%稀释剂。该新颖口服制剂可实现将普瑞巴林延迟释放的特性,并能够延长普瑞巴林在胃和小肠上端的滞留时间,提高生物利用度,获得平稳的血药浓度,减少服用次数。
Drugs covered by this patent
- Lyrica (Pregabalin) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.